Stay updated with breaking news from Fairooz Kabbinavar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-New clinical datafrom second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -
Onvansertib either alone or with standard of care many benefit patients with metastatic pancreatic ductal adenocarcinoma and those with pretreated SCLC.
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0...
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical...
- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - - First-line mCRC represents substantial increase in patient...